Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?

Lancet Oncol. 2011 Mar;12(3):209-11. doi: 10.1016/S1470-2045(11)70013-4. Epub 2011 Feb 25.
No abstract available

MeSH terms

  • Anthracyclines / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Drug Therapy, Combination
  • Female
  • Humans
  • Neoadjuvant Therapy*
  • Receptor, ErbB-2
  • Trastuzumab

Substances

  • Anthracyclines
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab